MOUNTAIN VIEW, Calif., Sept. 26 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a leading developer of novel inhaled drug products and systems, today announced that it will present a company update at the UBS Global Life Sciences Conference which is being held September 25-28 at the Grand Hyatt New York in New York City. Timothy S. Nelson, MAP’s President and CEO, will make the company’s presentation on Tuesday, September 26, 2006, at 3:00 pm (EDT).
About MAP Pharmaceuticals, Inc.
Located in Mountain View, California, MAP Pharmaceuticals is a specialty pharmaceutical company focused on the development of innovative therapies and inhalation delivery systems to treat a broad range of respiratory and systemic diseases. MAP’s lead product candidates are a proprietary formulation of inhaled DHE for the treatment of migraines and a proprietary formulation of budesonide for the treatment of asthma in both pediatric and adult populations. Additional information about MAP Pharmaceuticals can be found on the MAP website at http://www.mappharma.com .
MAP Pharmaceuticals, Inc.
CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122, orljohnson@mappharma.com
Web site: http://www.mappharma.com/
